Business
Avalon GloboCare Announces Closing of up to $9.75 Million Private Placement Priced At-the-Market under Nasdaq Rules
$3.25 Million Upfront With up to Approximately $6.5 Million of Potential Aggregate Proceeds Upon the Exercise in Full of WarrantsFREEHOLD, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for th
About this update from Avalon Globocare Corp.
[{"type":"image","alt":"Avalon GloboCare Corp.","displaySize":"","headline":null,"caption":"Avalon GloboCare Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/ca14a367dd280e883fb2c073629a950a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/f2z2WLiGU9diHcPeWDzacQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ca14a367dd280e883fb2c073629a950a","width":300,"height":79}},"lazy":false},{"type":"text","content":"$3.25 Million Upfront With up to Approximately $6.5 Million of Potential Aggregate Proceeds Upon the Exercise in Full of Warrants","length":129,"tagName":"p"},{"type":"text","content":"FREEHOLD, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a diversified company focused on the development of precision diagnostic consumer products and generative AI publishing and software, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of 6,372,550 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to an aggregate of 6,372,550 shares of common stock and Series A-2 warrants to purchase up to an aggregate of 6,372,550 shares of common stock, at a purchase price of $0.51 per share (or pre-funded warrant in lieu thereof) and associated warrants. The warrants have an exercise price of $0.51 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants. The Series A-1 warrants will expire five years from the date of stockholder approval and the Series A-2 warrants will expire eighteen months from the date of stockholder approval.","length":1131,"tagName":"p"},{"type":"text","content":"H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. Roth Capital Partners acted as financial advisor to the Company.","length":147,"tagName":"p"},{"type":"text","content":"The aggregate gross proceeds to the Company from the offering were approximately $3.25 million, before deducting placement agent fees and other offering expenses. The potential additional gross proceeds to the Company from the warrants, if fully-exercised on a...